Posted in | News

URALCHEM Partners with Riga Commercial Port to Build New Commercial Terminal

A partnership construction venture between URALCHEM Freight and SIA Rigas tirdzniecibas osta (RTO) – RIGA COMMERCIAL PORT, for the building of a terminal to handle and store fertilizers has received approval of Riga City Council on 26th July this year.

The total value of the project is estimated to be around $ 70 million. The first phase with a handling capacity of 2 million tons annually is expected to go on stream by the 3rd quarter of 2013.

URALCHEM Freight and RTO have contracted an accord in 2009 to construct the terminal. For the purpose of completing the project the two have launched Riga Fertilizer Terminal with 51% participation from URALCHEM holding and 49% by RTO. Presently the project’s design stage will be completed soon. The project construction work is anticipated to commence in September 2011. The proposed facility will remain spread over to around 12 ha of area in the Free Port of Riga.

The proposed terminal construction will be built with advanced engineering, to enable storing and transferring of fertilizer within the covered facilities to safeguard the environment and to protect the people live in Riga.

Dmitry Konyaev, URALCHEM, OJSC’s, CEO, said that the construction of the terminal has become one among the important projects of the company. He added that the company is planning to have its own transshipment installations on the Baltic Sea to achieve improved flexibility in fulfilling customer demands, to bring down the transport costs and to optimize logistics flows and above all to improve the position of the company in the global market.

Source: http://www.uralchem.com/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 22). URALCHEM Partners with Riga Commercial Port to Build New Commercial Terminal. AZoBuild. Retrieved on May 27, 2024 from https://www.azobuild.com/news.aspx?newsID=14287.

  • MLA

    Scanlon, Joel. "URALCHEM Partners with Riga Commercial Port to Build New Commercial Terminal". AZoBuild. 27 May 2024. <https://www.azobuild.com/news.aspx?newsID=14287>.

  • Chicago

    Scanlon, Joel. "URALCHEM Partners with Riga Commercial Port to Build New Commercial Terminal". AZoBuild. https://www.azobuild.com/news.aspx?newsID=14287. (accessed May 27, 2024).

  • Harvard

    Scanlon, Joel. 2019. URALCHEM Partners with Riga Commercial Port to Build New Commercial Terminal. AZoBuild, viewed 27 May 2024, https://www.azobuild.com/news.aspx?newsID=14287.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.